-
1.发明申请METHODS OF EVALUATING VIRAL ENTRY INHIBITORS USING PATIENT DERIVED ENVELOPE PROTEIN CONSTRUCTS 有权使用患者衍生的包膜蛋白质构建体评估病毒入侵抑制剂的方法公开(公告)号：US20060160185A1
公开(公告)日：2006-07-20
申请号：US11323189
申请日：2005-12-29
CPC分类号： C12Q1/70 , C12Q1/6897 , C12Q1/703 , G01N33/5091 , G01N33/56983
摘要： The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译： 本发明提供了一种用于鉴定化合物是否抑制病毒进入细胞的方法，其包括：（a）从感染病毒的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。
-
2.发明申请METHODS OF EVALUATING CELL SURFACE RECEPTOR BINDING OF A PATIENT DERIVED POPULATION OF VIRAL ENVELOPE PROTEIN CONSTRUCTS 有权评估病毒传播病毒人群蛋白质构建体细胞表面受体结合的方法公开(公告)号：US20060183110A1
公开(公告)日：2006-08-17
申请号：US11233461
申请日：2005-09-21
IPC分类号： C12Q1/70
CPC分类号： C12Q1/70 , C12Q1/6897 , C12Q1/703 , G01N33/5091 , G01N33/56983
摘要： The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which, lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译： 本发明提供了一种用于鉴定化合物是否抑制病毒进入细胞的方法，其包括：（a）从感染病毒的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。
-
3.发明申请Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays 审中-公开用重组病毒测定法评估病毒受体/辅助受体使用的组合物和方法以及病毒进入抑制剂公开(公告)号：US20050214743A1
公开(公告)日：2005-09-29
申请号：US10504921
申请日：2003-02-14
申请人： Douglas Richman , Mary Wrin , Susan Little , Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
发明人： Douglas Richman , Mary Wrin , Susan Little , Christos Petropoulos , Neil Parkin , Jeannette Whitcomb , Wei Huang
CPC分类号： G01N33/56988 , C07K14/005 , C07K14/16 , C07K14/162 , C07K16/08 , C07K16/10 , C12Q1/6897 , C12Q1/703 , G01N33/5044 , G01N33/5091 , G01N33/56983 , G01N2333/16
摘要： The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic add of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
摘要翻译： 本发明提供了鉴定化合物是否抑制病毒进入细胞的方法，该方法包括：（a）从病毒感染的患者获得编码病毒包膜蛋白的核酸; （b）共转染入第一细胞（i）步骤（a）的核酸添加，和（ii）缺乏编码包膜蛋白的核酸的病毒表达载体，其包含指示核酸，其产生 使得第一细胞产生包含由患者获得的核酸编码的包膜蛋白的病毒颗粒; （c）在化合物存在下使步骤（b）中产生的病毒颗粒与第二细胞接触，其中第二细胞表达病毒结合的细胞表面受体; （d）测量由第二细胞产生的信号量以确定病毒颗粒的感染性; 和（e）将步骤（d）中测量的信号量与在不存在化合物时产生的信号量进行比较，其中在化合物存在下测量的信号量减少表明化合物抑制病毒进入 进入第二个细胞。
-
4.发明授权Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy 有权用于确定受试者是否将受益于共受体抑制剂治疗的组合物和方法公开(公告)号：US09581595B2
公开(公告)日：2017-02-28
申请号：US12527863
申请日：2008-02-26
IPC分类号： G01N33/00 , G01N33/569
CPC分类号： C12Q1/703 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/56988 , G01N2333/16 , G01N2333/162 , G01N2800/52
摘要： The present invention provides methods and compositions for determining whether a subject would benefit from co-receptor inhibitor therapy. In certain aspects, the methods can be used to determine whether a subject infected with a dual-mixed tropic population of HIV would benefit from CCCR5-inhibitor therapy or CXCR4-inhibitor therapy, the methods comprising determining whether the HIV population is a homogeneous or heterogeneous population of HIV, wherein the nature of the homogenous or heterogenous population of HIV indicates whether the patient would benefit from co-receptor inhibitor therapy.
摘要翻译： 本发明提供了用于确定受试者是否将受益于共受体抑制剂治疗的方法和组合物。 在某些方面，该方法可用于确定受艾滋病双重混合热带人群感染的受试者是否将受益于CCCR5抑制剂治疗或CXCR4抑制剂治疗，所述方法包括确定HIV群体是否是均质或异质性 艾滋病毒的人群，其中艾滋病的同源或异质群体的性质表明患者是否可以从共同受体抑制剂治疗中受益。
-
5.发明申请Method for determining reduced susceptibility of HIV to protease inhibitor treatment 审中-公开确定HIV对蛋白酶抑制剂治疗的易感性降低的方法公开(公告)号：US20050214749A1
公开(公告)日：2005-09-29
申请号：US11051812
申请日：2005-02-04
摘要： The present invention provides methods and devices for predicting whether a HIV variant will be resistant to an antiviral drug based on the variant's genotype. In one aspect, methods are provided comprising determining whether a combination of protease inhibitor resistance mutations meet certain conditions, as disclosed herein, thereby assessing the effectiveness of ritonavir-boosted indinavir therapy in the HIV-infected subject. Computer implemented methods comprising determining HIV resistance are provided.
摘要翻译： 本发明提供了用于基于变体的基因型来预测HIV变体是否能够抗抗病毒药物的方法和装置。 在一个方面，提供了方法，其包括确定蛋白酶抑制剂抗性突变的组合是否满足本文所公开的某些条件，从而评估利托那韦加强的茚地那韦治疗在HIV感染受试者中的有效性。 提供了包括确定HIV抗性的计算机实施方法。
-
公开(公告)号：US20060003319A1
公开(公告)日：2006-01-05
申请号：US11146879
申请日：2005-06-06
申请人： Christos Petropoulos
发明人： Christos Petropoulos
IPC分类号： C12Q1/70
CPC分类号： C12Q1/703 , C07K14/005 , C12N7/00 , C12N2740/16062 , C12N2740/16122 , C12N2800/107 , C12N2800/40 , C12Q1/04 , C12Q1/66 , G01N33/5008 , G01N2333/16 , G01N2333/162
摘要： The invention provides a method for determining whether a human immunodeficiency virus is resistance to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.
-
公开(公告)号：US20050214746A1
公开(公告)日：2005-09-29
申请号：US10846181
申请日：2004-05-14
申请人： Daniel Capon , Christos Petropoulos
发明人： Daniel Capon , Christos Petropoulos
IPC分类号： C12N15/867 , C12Q1/18 , C12Q1/68 , C12Q1/70 , G01N33/50
CPC分类号： C12N15/86 , C12N2740/16043 , C12N2830/00 , C12N2830/15 , C12N2830/60 , C12N2840/20 , C12N2840/203 , C12N2840/206 , C12N2840/44 , C12Q1/18 , C12Q1/6881 , C12Q1/6897 , C12Q1/701 , C12Q1/703 , C12Q1/707 , C12Q2600/158 , G01N33/5023 , G01N2333/16 , G01N2800/52 , C12Q2545/113
摘要： This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biological effectiveness of a candidate anti-viral drug compound. Compositions including resistance test vectors comprising a patient-derived segment and an indicator gene and host cells transformed with the resistance test vectors are provided.
-
8.发明申请Production of infectious hepadnavirus particles containing foamy retrovirus envelope proteins and methods of using the same 审中-公开含有泡沫逆转录病毒包膜蛋白的感染性肝炎病毒颗粒的生产及其使用方法公开(公告)号：US20050074888A1
公开(公告)日：2005-04-07
申请号：US10723798
申请日：2003-11-25
申请人： Christos Petropoulos
发明人： Christos Petropoulos
CPC分类号： C12Q1/02 , C12N15/86 , C12N2730/10143 , C12N2810/6054 , G01N33/56983 , G01N2800/52
摘要： The invention provides a method for producing a hepadnavirus virion that is infectious in vitro which comprises:(a) introducing into a cell (i) a hepadnavirus genome expression vector and (ii) a foamy retrovirus envelope expression vector which comprises a nucleic acid encoding at least a fragment of a foamy virus envelope protein, and (b) culturing the cell thereby producing hepadnavirus virions comprising at least a fragment of a foamy virus envelope protein, wherein the hepadnavirus virions are infectious in vitro. A method for determining susceptibility for an anti-hepadnavirus drug, a method for determining replication capacity of a hepadnavirus from an infected patient, and method for identifying a mutation in a hepadnavirus nucleic acid that confers resistance to an anti-hepadnavirus drug are also provided.
摘要翻译： 本发明提供了一种用于产生体外感染性的肝炎链球菌病毒粒子的方法，其包括：（a）向细胞（i）引入肝炎链脲病毒基因组表达载体和（ii）泡沫逆转录病毒包膜表达载体，其包含编码 至少一个泡沫病毒包膜蛋白的片段，和（b）培养细胞，从而产生包含泡沫病毒包膜蛋白的至少一个片段的肝炎链球菌病毒粒子，其中肝炎病毒颗粒体外感染。 还提供了用于确定抗肝炎疫苗病毒药物的敏感性的方法，用于确定来自感染患者的肝炎病毒的复制能力的方法，以及鉴定赋予抗肝炎病毒药物抗性的肝炎链球菌核酸中的突变的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.064 秒)
